Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

My main thesis is to explain why AbbVie Inc. remains my top 2023 dividend stock in the healthcare space despite its near-record stock prices. The thesis is best illustrated by comparison and contrast against another dividend champ, Johnson & Johnson.

Better 2023 Dividend Stock: AbbVie Or Johnson & Johnson?

Ever since its split from Abbott Laboratories in 2012 AbbVie has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year.

AbbVie: Modelling The Post Humira Bull Case To 2030 - The Outlook Is Bright

Dollar Tree

Coca-Cola

Medical Properties Trust

Procter & Gamble

Global X Superdividend ETF

W. P. Carey

At the rate things are going, a recession is likely. All thanks to the Federal Reserve, which once tried — laughably — to convince us inflation was transitory.

7 Stocks Every Smart Investor Should Own in 2023

Axsome Therapeutics

Vertex Pharmaceuticals

These companies have what it takes to drive long-term share performance.

3 Unstoppable Stocks to Keep Buying in 2023

CRISPR Therapeutics

CureVac B.V

Exelixis

Incyte

Pfizer

Sarepta Therapeutics

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.

7 Biotech Stocks That Will Make You Rich in 10 Years

Amgen

Boeing

General Dynamics

Kimberly-Clark

Kenvue

L3Harris

Lockheed Martin

Altria

Merck

Northrop Grumman

Philip Morris

Raytheon Technologies

Investing in blue-chip companies that pay dividends and relentlessly focusing on reinvesting the proceeds is a proven strategy for reliable long-term returns. But what about the occasional black swan? Potentially devastating litigation? Overlooked liabilities on the balance sheet? Financial engineering?

Blue-Chip Stocks And Red Flags - Things To Consider In Your Due Diligence

Microsoft

Over the past 10 years, these stocks have each risen by more than 340%.

2 Cheap Growth Stocks That Can Set You Up for Life

With JUVÉDERM® VOLUX™ XC, You Can Receive Non-Surgical Jawline Augmentation in Your Aesthetic Provider's Office IRVINE, Calif. , Jan. 18, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM® VOLUX™ XC.

JUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE

Apple

Abbott Labs

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

Amazon

Bank of America

Becton, Dickinson and Co.

Bristol-Myers

Citigroup

Cardinal Health

Caterpillar

Cisco Systems

CVS Health

Chevron

Disney

Digital Realty Trust

Duke Energy

Emerson Electric

Enterprise Products Partners

Eaton

General Mills

Alphabet

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing.

My Dividend Growth Portfolio - Q4 2022 Summary

AbbVie is a quality BBB+ S&P credit rated healthcare stock with a 3.9% yield. It has 11 years of a rising dividend and an amazing 5-year dividend growth rate of 17.7%.

AbbVie : To Buy Or Not To Buy

Lowe's

PepsiCo

These 3 Dividend Kings offer value and yield to investors and could outperform the group in 2023. That's good news for income investors.

4 High-Yield Dividend Kings For 2023

Last month, one of its anti-psychotic drugs received approval from the Food and Drug Administration for another indication.

Could This FDA Approval Boost AbbVie's Stock?

The Results Are Clear - A Scientifically Proven Path to Targeting the Appearance of Hyperpigmentation and Improving Skin Tone and Texture IRVINE, Calif. , Jan. 17, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited SkinMedica ® Even & Correct Collection.

SkinMedica® Launches Even & Correct

This year isn't starting on the best of notes for the drugmaker.

With Competition on the Rise, Is AbbVie's Dividend Safe?

Biogen

UnitedHealth Group

The fountain of youth might not be a myth in the future.

This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich

The stock offers an attractive yield, but investors need to brace for declining revenue this year.

Is AbbVie a Good Dividend Stock to Buy on the Dip?

American States Water

PPG Industries

Rely upon income-generating stocks to see your portfolio through times of upheaval.

5 Dividend Kings I Bought for My Portfolio

News for AbbVie Stock (ABBV)